Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Solid Biosciences Inc.NASDAQ: SLDB

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2022
-1315.2%
Year-over-year change
-784.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How SLDB compares with its peers on the latest reported figures

SLDB Competitors Peer median
Operating Margin for SLDB and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202611.5% -29.2 pp+113.5 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-1.9% +3.4 pp+27.5 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-131.9% +329.0 pp+600.7 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-203.5% +883822.6 pp+3329.3 pp
SLDBSolid Biosciences Inc.FY2025— ——
EWTXEdgewise Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
NGNENeurogene Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding SLDB) -66.9%+166.2 pp+357.1 pp

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.62M8.09M000
Cost of Revenue002.58M2.46M1.64M
Gross Profit13.62M8.09M(2.58M)(2.46M)(1.64M)
Gross Margin100.0%100.0%———
Research & Development58.74M78.42M76.56M96.43M140.33M
Selling, General & Admin27.14M28.95M27.75M33.3M38.88M
Operating Expenses85.87M114.55M101.73M127.27M177.57M
Depreciation & Amortization2.96M2.41M2.58M2.46M1.64M
EBITDA(69.22M)(96.87M)(93.43M)(121.9M)(172.69M)
EBITDA Margin-508.3%-1196.8%———
Operating Income(72.25M)(106.45M)(104.32M)(129.73M)(179.21M)
Operating Margin-530.5%-1315.2%———
Interest Income64K2.62M7.14M9.47M9.9M
Interest Expense000340K0
Other Income / Expenses66K20.47M8.3M5.03M4.88M
Income Before Tax(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Pre-Tax Margin-530.0%-1062.3%———
Income Tax Expense00000
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Net Margin-530.0%-1062.3%———
EPS (Basic)(10.14)(10.10)(4.83)(3.06)(1.99)
EPS (Diluted)(10.14)(10.10)(4.83)(3.06)(1.99)
Weighted Avg Shares7.12M8.51M19.88M40.82M87.5M
Weighted Avg Shares (Diluted)7.12M8.51M19.88M40.82M87.5M

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.